Atazanavir is a potent, novel and highly selective inhibitor of the HIV-1 protease, with a low pill burden and once-daily dosing. Clinical studies have shown atazanavir to be the first protease inhibitor (PI) to have equivalent efficacy to efavirenz over a 48-week period of follow-up in Pl-treatment-naïve patients. Loss of susceptibility to atazanavir in PI-naïve patients occurs infrequently and is not associated with cross-resistance to other PIs. In clinical trials, atazanavir has shown better gastrointestinal tolerability than other PIs. Also, unlike other PIs, atazanavir has been associated with decreases, or only minimal increases, in lipid parameters such as low-density lipoprotein cholesterol and triglycerides.
O'MaraE, SmithJ, OlwenSJBMS-232632: Single and multiple oral dose safety and pharmacokinetic study in healthy volunteers [Abstract 604]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago 1999
2.
PantaleoG, SanneI, CahnPAtazanavir (BMS-232632): 48-week safety and efficacy vs nelfinavir, each in combination with stavudine and lamivudine, in treatment-naïve, HIV-positive subjects (BMS AI424-008) (O11). 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, Athens 2001
3.
MurphyR, PokrovskiyV, RozenbaumWLong-term efficacy and safety of atazanavir (ATV) with stavudine (d4T) and lamivudine (3TC) in patients previously treated with nelfinavir (NFV) or ATV: 108-week results of BMS Study 008/044 [Poster G1-36]. 10th Conference on Retroviruses and Opportunistic Infections, Boston 2003
4.
SquiresKE, ThiryA, GiordanoM. Atazanavir (ATV) QD and efavirenz (EFV) QD with fixed-dose ZDV+3TC: comparison of antiviral efficacy and safety through wk 24 (AI424-034) [Poster H-1076]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego 2002
5.
StaszewskiS, Morales-RamirezJ, TashimaKTEfavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults.N Engl J Med1999341: 186573
6.
MontanerJSG, SaagMS, BarylskiCFOCUS study — saquinavir QD regimen versus efavirenz QD regimen 48 week analysis in HIV infected patients [Abstract H-167]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego 2002
7.
BartlettJA, JohnsonJ, HerreraGAbacavir/lamivudine (ABC/3TC) in combination with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS400001 (CLASS) preliminary 48 week results (TuOrB1189).XIV International AIDS Conference, Barcelona2002
8.
RobbinsG, ShaferR, SmeatonLAntiretroviral strategies in naïve HIV+ subjects: comparison of sequential 3-drug regimens (ACTG 384) (LbOr20A).XIV International AIDS Conference, Barcelona2002
9.
MurphyR, ThiryA, ManciniMTwelve weeks of atazanavir treatment reverses nelfinavir-associated hyperlipidemia: Results from BMS AI424-044.Antivir Ther2002; 7: L10
10.
SensionM, ThiryA, GiordanoM, for the AI424-034 International Study team. Absence of insulin resistance through week 24 with atazanavir once daily and efavirenz once daily, each with twice-daily fixed-dose zidovudine plus lamivudine [Abstract 36]. Presented at 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV Infection, San Diego 2002.Antivir Ther2002; 7: L26
11.
IloejeU, YuanY, TuomariAProtease inhibitors may increase risk of cardiovascular disease in HIV-infected patients [Abstract 746]. 10th Conference on Retroviruses and Opportunistic Infections, Boston 2003
12.
GroverSA, ZowallH, BrewerCHighly active antiretroviral therapy (HAART) for HIV infections and dyslipidemia: Estimating the impact of nelfinavir and atazanavir on cardiovascular (CVD) risk and life expectancy (LE) after adjustment for HIV related mortality. 4th Scientific Forum on Quality of Care and Outcomes Research in CVD and Stroke, Washington 2002
13.
O'MaraE, RandallD, PassarellJPopulation pharmacodynamic assessment of atazanavir exposure, uridine diphosphate-glucoronosyl transferase (UGT) 1A1 genotype and safety in healthy subjects [Abstract A-1253]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego 2002
14.
ColonnoRJ, FribingJ, RoseREIdentification of amino acid substitutions correlated with reduced atazanavir susceptibility in patients treated with atazanavir-containing regimens.Antivir Ther2002; 7: S4
